Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Intrinsic Value
Hangzhou Tigermed Consulting Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. [ Read More ]
The intrinsic value of one
Hangzhou Tigermed Consulting Co Ltd
stock under the Base Case scenario is
91.65
CNY.
Compared to the current market price of 53.01 CNY,
Hangzhou Tigermed Consulting Co Ltd
is
Undervalued by 42%.
Hangzhou Tigermed Consulting Co Ltd's market capitalization is 39.7B CNY.
Hangzhou Tigermed Consulting Co Ltd stock price is 53.01 CNY.
Hangzhou Tigermed Consulting Co Ltd stock price (53.01 CNY) is 42% less than its Intrinsic Value (91.65 CNY).
Hangzhou Tigermed Consulting Co Ltd stock price (53.01 CNY) is 2% less than its DCF Value (53.92 CNY). Open DCF Valuation
Hangzhou Tigermed Consulting Co Ltd stock price (53.01 CNY) is 59% less than its Relative Value (129.38 CNY). Open Relative Valuation
Hangzhou Tigermed Consulting Co Ltd has upside potential of 61% compared to the average analyst price target.
Open Wall St Estimates
Hangzhou Tigermed Consulting Co Ltd has positive three-year average ROIC (Return on Invested Capital): 10%. The company is efficient at using invested capital to generate operating income.
Hangzhou Tigermed Consulting Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 10%.
Hangzhou Tigermed Consulting Co Ltd's Revenue has grown by 4% over the past 12 months.
Hangzhou Tigermed Consulting Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
Hangzhou Tigermed Consulting Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 11% to 7%.
Hangzhou Tigermed Consulting Co Ltd has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
Hangzhou Tigermed Consulting Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 19% to 10%.
Hangzhou Tigermed Consulting Co Ltd's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
Hangzhou Tigermed Consulting Co Ltd has positive Operating Income for the last twelve months.
Hangzhou Tigermed Consulting Co Ltd has positive Gross Profit for the last twelve months.
Hangzhou Tigermed Consulting Co Ltd's Revenue has been growing by an exceptional 32% per year for the last 3 years.
Hangzhou Tigermed Consulting Co Ltd has positive Free Cash Flow for the last twelve months.
Hangzhou Tigermed Consulting Co Ltd has positive Net Income for the last twelve months.
Hangzhou Tigermed Consulting Co Ltd's short-term assets (11B CNY) exceed its short-term liabilties (4B CNY).
Hangzhou Tigermed Consulting Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (7B CNY) than debt (3B CNY).
Hangzhou Tigermed Consulting Co Ltd's Altman Z-Score is very high and is equal to 3.8.
Hangzhou Tigermed Consulting Co Ltd's long-term assets (30B CNY) exceed its long-term liabilties (9B CNY).
Hangzhou Tigermed Consulting Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.14.
Valuation Backtest
Hangzhou Tigermed Consulting Co Ltd
Run backtest to discover the historical profit from buying and selling
Hangzhou Tigermed Consulting Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Hangzhou Tigermed Consulting Co Ltd
Balance Sheet Decomposition
Hangzhou Tigermed Consulting Co Ltd
| Current Assets | 11.3B |
| Cash & Short-Term Investments | 7.5B |
| Receivables | 3.7B |
| Other Current Assets | 126.7m |
| Non-Current Assets | 18.3B |
| Long-Term Investments | 13.2B |
| PP&E | 1.5B |
| Intangibles | 3.1B |
| Other Non-Current Assets | 492.5m |
| Current Liabilities | 4.1B |
| Accounts Payable | 249.3m |
| Accrued Liabilities | 461.5m |
| Short-Term Debt | 2B |
| Other Current Liabilities | 1.4B |
| Non-Current Liabilities | 4.5B |
| Long-Term Debt | 857.3m |
| Other Non-Current Liabilities | 3.7B |
Earnings Waterfall
Hangzhou Tigermed Consulting Co Ltd
|
Revenue
|
7.4B
CNY
|
|
Cost of Revenue
|
-4.5B
CNY
|
|
Gross Profit
|
2.8B
CNY
|
|
Operating Expenses
|
-1.1B
CNY
|
|
Operating Income
|
1.7B
CNY
|
|
Other Expenses
|
312.1m
CNY
|
|
Net Income
|
2B
CNY
|
Free Cash Flow Analysis
Hangzhou Tigermed Consulting Co Ltd
Profitability Score
Profitability Due Diligence
Hangzhou Tigermed Consulting Co Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Hangzhou Tigermed Consulting Co Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hangzhou Tigermed Consulting Co Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Hangzhou Tigermed Consulting Co Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hangzhou Tigermed Consulting Co Ltd
According to Wall Street analysts, the average 1-year price target for
Hangzhou Tigermed Consulting Co Ltd
is 85.09 CNY
with a low forecast of 40 CNY and a high forecast of 260.4 CNY.
Shareholder Return
Price
Hangzhou Tigermed Consulting Co Ltd
| Average Annual Return | 42.52% |
| Standard Deviation of Annual Returns | 88.93% |
| Max Drawdown | -81% |
| Market Capitalization | 39.7B CNY |
| Shares Outstanding | 749 292 992 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Hangzhou Tigermed Consulting Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Hangzhou Tigermed Consulting Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Hangzhou, Zhejiang and currently employs 8,326 full-time employees. The company went IPO on 2012-08-17. Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The firm operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The firm conducts its businesses in the domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Hangzhou Tigermed Consulting Co Ltd
stock under the Base Case scenario is
91.65
CNY.
Compared to the current market price of 53.01 CNY,
Hangzhou Tigermed Consulting Co Ltd
is
Undervalued by 42%.
You don't have any saved screeners yet
